• For children who are undergoing anti-tuberculosis treatment with rifampicin, higher dosages of ritonavir may be needed for pharmacokinetic enhancement of the combined protease inhibitor. (who.int)
  • Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. (guidetherapeutiquevih.com)
  • Observed in patients receiving antiretroviral therapy. (nih.gov)
  • 3000% increase in simvastatin concentrations, simvastatin should never be given concurrently with any protease inhibitor. (ebmconsult.com)
  • However, use of simvastatin in HIV-infected patients receiving highly active antiretroviral therapy (HAART) is limited by the potential for this drug to interact with antiretroviral medications, specifically drugs from the protease inhibitor class. (ebmconsult.com)
  • One key study showed a 3,059% increase in simvastatin exposure when coadministration with the protease inhibitor combo, saquinavir (Invirase) and ritonavir (Norvir).2 The mechanism for the interaction is potent inhibition of the cytochrome P450 3A4 enzyme by all known protease inhibitors. (ebmconsult.com)
  • In particular, CYP450 3A4 is responsible for the vast majority of simvastatin metabolism and plasma clearance.3 Thus, protease inhibitor mediated inhibition of the CYP450 3A4 clearance pathway for simvastatin results in dangerously high concentrations of this statin. (ebmconsult.com)
  • One study reported that 21% of HIV infected patients were receiving a contraindicated statin with their PI.11 Therefore, the combination of simvastatin and PIs should be avoided and other statin options (such as pravastatin which does not undergo CYP450 metabolism) are preferred.12 Use of simvastatin with nevirapine, efavirenz, or etravirine may be acceptable. (ebmconsult.com)
  • Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy. (ebmconsult.com)
  • Concomitant use of indinavir with lovastatin or simvastatin is not recommended by the FDA, and interactions with pravastatin and fluvastatin have not been studied. (medscape.com)
  • The recommended dose is 100 mg ritonavir once or two times per day, depending on the concurrently used protease inhibitor. (who.int)
  • Depending on the specific protease inhibitor with which it is co-administered, ritonavir may be appropriate for use with caution in patients with renal insufficiency. (who.int)
  • For specific dosing information in patients with renal impairment, refer to the product information of the co-administered protease inhibitor. (who.int)
  • In the absence of pharmacokinetic studies in patients with stable severe hepatic impairment (Child Pugh grade C) without decompensation, caution should be exercised when ritonavir is used as a pharmacokinetic enhancer as increased levels of the co-administered protease inhibitor may occur. (who.int)
  • Specific recommendations for use of ritonavir as a pharmacokinetic enhancer in patients with hepatic impairment are dependent on the protease inhibitor with which it is co-administered. (who.int)
  • Efavirenz is a non-nucleoside reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg. (nih.gov)
  • Ritonavir boosted protease inhibitor therapy was discontinued and he was placed on Raltegravir which is not known to inhibit CYP3A4. (springeropen.com)
  • Effective highly active antiretroviral therapy (HAART) for human immunodeficiency virus-1 (HIV) infection has led to marked improvement in life-expectancy for those infected with HIV. (opencardiovascularmedicinejournal.com)
  • His highly active antiretroviral therapy (HAART) since 2006 consisted of lamivudine 150 mg twice daily, zidovudine 300 mg twice daily and lopinavir-ritonavir 400-100 mg twice daily. (springeropen.com)
  • types of such statins are pravastatin and fluvastatin, that are much less potent lipid-lowering agents [12] relatively. (abic2004.org)
  • This review will focus on the clinical presentation of HIV and ART-associated dyslipidemia, what is known of its patho-physiology, including associations with use of specific antiretroviral medications, and suggest screening and management strategies. (opencardiovascularmedicinejournal.com)
  • Other medical conditions included coronary artery disease, dyslipidemia and GERD treated with aspirin, clopidogrel, omeprazole, pravastatin and niacin. (springeropen.com)
  • Saquinavir 1000 mg twice daily with ritonavir 100 mg twice daily in antiretroviral treatment (ART)- experienced patients. (who.int)
  • Herein we present one such interaction wherein a 57 year old gentleman with human immunodeficiency virus (HIV) infection on highly active antiretroviral therapy that included ritonavir, had addition of fluticasone inhaler to his medication repertoire for treatment of chronic obstructive pulmonary disease. (springeropen.com)
  • These patients often are receiving other medications, including antiretrovirals that interfere with metabolism or elimination of OI medications. (hiv.gov)
  • It is taken in combination with other antiretroviral medications. (medixrx.com)
  • Conclusions In dyslipidemic HIV+ individuals on PI therapy, the association of ezetimibe+fenofibrate works more effectively than pravastatin monotherapy in enhancing lipid profile and can be well tolerated. (abic2004.org)
  • These morbidities, particularly premature cardiovascular disease, are thought to be related to a combination of the effects of an ageing HIV-infected population coupled with long-term effects of HIV infection and antiretroviral therapy (ART). (opencardiovascularmedicinejournal.com)
  • Human immunodeficiency virus (HIV) infection has evolved from a disease that was predictably fatal to a chronic disease that can be effectively managed with contemporary antiretroviral therapy (ART) regimens. (medscape.com)
  • Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH. (go.jp)
  • high-density lipoprotein (HDL) cholesterol improved (4410 to 5312 mg/dl, em p /em 0.005) and triglycerides decreased (from 265118 mg/dl to 14937 mg/dl, em p /em 0.001) in the ezetimibe+fenofibrate group, whereas both guidelines remained unchanged in the pravastatin group. (abic2004.org)
  • Possible drug-drug interactions should be taken into consideration when selecting an antiretroviral (ARV) regimen. (medscape.com)
  • For more information regarding specific drug interactions, see the Medscape Drug Interaction Checker or the NIH Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents . (medscape.com)
  • Adults with HIV or AIDS may be at an increased risk for development of coronary heart disease due to many factors, including the effects of increasingly older age of patients with HIV and long-term exposure and side effects to antiretroviral therapies that can cause high cholesterol and other metabolic abnormalities," Craig Sponseller, vice president of medical affairs for Livalo's maker, Kowa Pharmaceuticals America, told HIV Plus . (hivplusmag.com)
  • Livalo provided significantly greater low-density lipoprotein reduction compared with pravastatin in HIV-infected adults with high cholesterol," according to data presented by Kowa at the Endocrine Society's Annual Meeting last June. (hivplusmag.com)
  • Symtuza is a prescription medication used to treat HIV-1 infection in adults who have never used antiretroviral treatment or have been on stable antiretroviral treatment for 6 months or more with very low blood virus levels. (rxwiki.com)
  • HIV infection in treatment-experienced and treatment-naïve patients (in combination with other antiretrovirals). (drugguide.com)
  • PO capsules 1200 mg bid in combination with other antiretroviral agents. (medicscientist.com)
  • PO capsules 20 mg/kg bid or 15 mg/kg tid (max 2400 mg daily) in combination with other antiretroviral agents. (medicscientist.com)
  • Oral solution 22.5 mg/kg (1.5 ml/kg) bid or 17 mg/kg (1.1 ml/kg) tid (max 2800 mg) in combination with other antiretroviral agents. (medicscientist.com)
  • Antiretroviral treatment of HIV and healthy lifestyle help alleviate the symptoms of chronic inflammation, but can not completely and definitively eliminate it. (amedi.sk)
  • For drugs that should not be coadministered with ARVs at any dose, see NIH Guidelines for the Use Drugs That Should Not Be Used with Antiretroviral Agents . (medscape.com)
  • Some antiretroviral drugs may contribute to the risk of developing diabetes. (amedi.sk)
  • Antiretroviral drug chart A one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements. (aidsmap.com)
  • The availability of an increasing number of antiretroviral agents and the rapid evolution of new information has introduced substantial complexity into treatment regimens for persons infected with human immunodeficiency virus (HIV). (cdc.gov)
  • Antiretroviral regimens are complex, have serious side effects, pose difficulty with adherence, and carry serious potential consequences from the development of viral resistance because of nonadherence to the drug regimen or suboptimal levels of antiretroviral agents. (cdc.gov)
  • Human immunodeficiency virus (HIV) infection has evolved from a disease that was predictably fatal to a chronic disease that can effectively be managed with contemporary antiretroviral therapy (ART) regimens. (medscape.com)
  • Possible drug-drug interactions should be taken into consideration when selecting an antiretroviral (ARV) regimen. (medscape.com)
  • Indinavir binds to the protease active site and inhibits the activity of the enzyme. (nih.gov)
  • For more information regarding specific drug interactions, see the Medscape Drug Interaction Checker or the NIH Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents . (medscape.com)
  • For drugs that should not be coadministered with ARVs at any dose, see NIH Guidelines for the Use Drugs That Should Not Be Used with Antiretroviral Agents . (medscape.com)
  • To visit the Pediatric Antiretroviral Guidelines, visit this link . (guidelines.org.au)
  • Drug interactions with antiretrovirals are commonly caused by the inhibition or induction of hepatic drug metabolism. (medscape.com)